Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 32,500 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 32,500 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00. Following the sale, the chief financial officer owned 147,680 shares of the company’s stock, valued at $1,599,374.40. This trade represents a 18.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Alpha Tau Medical Stock Performance

NASDAQ DRTS opened at $10.24 on Friday. Alpha Tau Medical Ltd. has a 52-week low of $2.81 and a 52-week high of $11.62. The company has a 50-day simple moving average of $8.55 and a 200 day simple moving average of $6.96. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The company has a market capitalization of $924.98 million, a PE ratio of -15.28 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, research analysts predict that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Analyst Upgrades and Downgrades

DRTS has been the subject of a number of research reports. Citigroup increased their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Barclays increased their target price on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Finally, LADENBURG THALM/SH SH increased their target price on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $12.60.

Hedge Funds Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of DRTS. Apella Capital LLC bought a new position in shares of Alpha Tau Medical in the fourth quarter valued at approximately $1,892,000. Daytona Street Capital LLC bought a new position in shares of Alpha Tau Medical in the fourth quarter valued at approximately $749,000. Mariner LLC boosted its position in shares of Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after acquiring an additional 80,129 shares during the period. Millennium Management LLC boosted its position in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after acquiring an additional 70,081 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Alpha Tau Medical in the first quarter valued at approximately $286,000. 2.65% of the stock is currently owned by institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.